Document:

EXHIBIT
10.32

     

    FIRST
AMENDMENT to the May 26, 1993 License Agreement between ARCH

    Development
Corporation and GenVec, Inc.

     

    This
Amendment is effective as of December 31, 2001 between the University of Chicago
(the “University”), Dana Farber Cancer Institute, Inc. (“DFCI”), and GenVec
Corporation, a Delaware Corporation (“GenVec”).

     

    WHEREAS,
ARCH Development Corporation (“ARCH”), DFCI and GenVec entered into a License
Agreement effective on August 20, 1997 (the “Agreement”) that includes various
technologies discovered by Dr. Ralph Weichselbaum and colleagues while at the
University and Dr. Donald Kufe at DFCI;

     

    WHEREAS,
The University, under an agreement with its affiliated corporation, ARCH has the
right to license the Licensed Patents and other intellectual property assigned
to ARCH;

     

    WHEREAS,
GenVec, ARCH, DFCI and the University have identified a new invention of Dr.
Weichselbaum and colleagues at the University and DFCI which is deemed
complimentary to the business of GenVec but which does not fall within the
Licensed Patents found in Schedule A of the Agreement (the “Complimentary
Invention” as further described in Schedule A of this First
Amendment);

     

    WHEREAS,
GenVec desires to include the Complimentary Invention in the terms of the
Agreement and also desires certain modifications of the terms and conditions of
the Agreement for the Complimentary Invention; and;

     

    WHEREAS,
ARCH or the University and DFCI are or will become an assignee of the
Complimentary Invention;

     

    WHERAS,
the University has completed an inter-institutional agreement with DFCI giving
the University the right to exclusively license the Complimentary
Invention;

     

    WHEREAS,
ARCH, DFCI and the University are willing to amend the Agreement to include the
Complimentary Invention and to include such other modifications to the Agreement
as are listed below.

     

    NOW,
THEREFORE, in consideration of the mutual promises set forth herein and rights
obtained thereby, it is agreed as follows:

     

    
      	
               
      

            	
              1.

            	
              All
      references to “ARCH” in the Agreement shall be changed to
      “University”.

            

    

     

    
      	
               
      

            	
              2.

            	
              Paragraph
      3.A(1)(1) will be deleted in its entirety and replaced with the following:
      “$* at the time of the filing in the United States by Licensee or any
      Sublicensee of an NDA on a Licensed Product (such payment referred to as
      an “NDA Fee”), provided a Licensed Product utilizes the Complimentary
      Invention.  If Complimentary Invention is not utilized in an NDA
      on a Licensed Product, NDA”

            

    

     

    *The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	
               
      

            	
              3.

            	
              Paragraph
      3.B (2) will be amended to read as follows: “In the event that Licensee or
      its Sublicensee enters into a license agreement with any third party with
      respect to intellectual property rights which are necessary or useful for
      Licensee’s practice of the Licensed Patents or the manufacture, use,
      import and/or sale of any Licensed Product, Licensee and Sublicensees may
      offset any payments made in accordance with such license agreements
      against any amounts owed Licensors pursuant to Paragraph 3B herein, on a
      country-by-country basis, up to a maximum of * of the amounts due under
      Paragraph 3B.  Any such amounts which are not offset in any
      quarter may be carried forward until
applied.”

            

    

     

    
      	
               
      

            	
              4.

            	
              Paragraph
      4.A(1) shall be amended to include “Fulbright and Jaworski;” after the
      word “Borum” in line 3.

            

    

     

    
      	
               
      

            	
              5.

            	
              Paragraph
      5.A shall be amended to include

            

    

     

    
      	
               
      

            	
              “Resources
      will be allocated to support this technology in conjunction with GenVec’s
      ongoing program to advance TNFerade as a product
      candidate.  These resources will take several forms, including
      direct research funding of chemoinduction research in the laboratory of
      Ralph Weichselbaum, and internal work at GenVec to confirm hypotheses
      surrounding the chemoinduction work.  Upon generation of
      appropriate clinical data surrounding this technology and gaining required
      approvals to pursue clinical studies in this area, GenVec anticipates
      applying further resources to the technology, leading to development of
      safety and efficacy packages.”

            

    

     

    
      	
               
      

            	
              6.

            	
              Paragraph
      5.B. shall be amended as follows: “For the Complimentary Invention and
      within thirty (30) days of June 30th
      during the term of this Agreement, Licensee shall make a written report to
      UCTech, in such detail as UCTech may reasonably request, covering the
      preceding twelve (12) months and describing the progress of Licensee
      towards achieving the development and commercialization of Licensed
      Products relating to the Complimentary Invention.  Licensee
      agrees to immediately notify UCTech in writing when commercial products
      are first sold and when Licensee’s obligation to make running Royalty
      payments begins.

            

    

     

    
      	
               
      

            	
              7.

            	
              Paragraph
      11.E. is amended to read:

            

    

     

    
      	
               
      

            	
              If
      to UCTech:

            	
              UCTech,

            

    

    
      	
               
      

            	
              The
      University of Chicago

            

    

    
      	
               
      

            	
              5640
      South Ellis, Suite 405

            

    

    
      	
               
      

            	
              Chicago,
      IL 60637

            

    

    
      	
               
      

            	
              Attention:
      Director of Technology Transfer

            

    

     

    
      	
               
      

            	
              If
      to GenVec:

            	
              GenVec
      Inc.

            

    

    
      	
               
      

            	
              65
      West Watkins Mill Rd.

            

    

    
      	
               
      

            	
              Gaithersburg,
      MD 20878

            

    

    
      	
               
      

            	
              Attention:
      President

            

    

    
      	
               
      

            	
              With
      a copy to: Vice President, Corporate
Development

            

    

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              8.

            	
              Paragraph
      11.H. shall be deleted in its
entirety.

            

    

     

    In all
other respects the Agreement remains unmodified and in full force and
effect.

     

    UCTech,
DFCI and GenVec agree to the above amendments to the terms of the License
Agreement by the signing of this Amendment by their respective duly authorized
officers or representatives:

     

    IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by
their respective duly authorized officers or representatives on the Effective
Date above written.

     

    
      
        
          
            	
                    UCTech

                  	 
      	
                    GenVec
      Corporation

                  
	 
      	 
      	 
      
	
                    By:

                  	 
      	 
      	
                    By:

                  	 
      
	 
      	 
      	 
      
	
                    Alan
      E. P. Thomas

                  	 
      	
                    Thomas
      Smart

                  
	 
      	 
      	 
      
	
                    Director
      of Technology Transfer

                  	 
      	
                    Senior
      Vice President of Corporate

                  
	
                    Date:

                  	
                    2/13/2002

                  	 
      	
                    Development

                  
	 
      	 
      	 
      
	 
      	 
      	
                    Date:

                  	
                    2/27/2002

                  

          

        

      

    

    

    
      
        
          	
                  DFCI

                	 
      
	 
      	 
      
	
                  By:

                	 
      	 
      
	
                  Ruth
      Emyanitoff

                	 
      
	 
      	 
      
	
                  Director,
      Office of Technology Transfer

                	 
      
	
                  Date:

                	
                  2/21/2002

                	 
      

        

      

    

    
      
         

      

      
        3EXHIBIT
10.33

     

    SECOND
AMENDMENT TO LICENSE AGREEMENT

    The
University of Chicago, Dana Farber Cancer Institute and GenVec
Corporation

     

    This
Amendment to the License Agreement is entered into as of January 20, 2005, by
and between The University of Chicago ("University"), Dana Farber Cancer
Institute ("DFCI") and GenVec Corporation, a Delaware corporation ("GenVec")
(University, DFCI and GenVec may be referred to individually as a "Party" and
collectively as the "Parties");

     

    WHEREAS,
the Parties previously entered into that certain License Agreement effective on
August 20, 1997 ("AGREEMENT") that includes various technologies discovered by
Dr. Ralph Weichselbaum and colleagues while at University and Dr. Donald Kufe at
DFCI, and

     

    WHEREAS,
the Parties previously entered into a First Amendment of the AGREEMENT effective
December 31, 2001, and

     

    WHEREAS,
the Parties desire to further amend the AGREEMENT;

     

    NOW,
THEREFORE, in consideration of the premises and the covenants contained herein,
the Parties hereby agree to amend the indicated sections of the AGREEMENT as
follows:

     

    
      	
               
      

            	
              1.

            	
              Paragraph
      4.A(1) shall be amended to read: "University shall be responsible for the
      filing, preparation, registration, prosecution and maintenance of the
      Licensed Patents; provided, however, University and Licensee shall
      mutually agree to the selection of patent counsel for such filing,
      prosecution and maintenance of all patent applications and patents within
      the Licensed Patents."

            

    

     

    
      	
               
      

            	
              2.

            	
              Paragraph
      11.E shall be amended to read:

            

    

    
       

      
        
          	
                  If
      to University:

                	
                  UCTech

                
	 
      	
                  Office
      of Technology and Intellectual Property

                
	 
      	
                  The
      University of Chicago

                
	 
      	
                  5555
      South Woodlawn Avenue

                
	 
      	
                  Suite
      300

                
	 
      	
                  Chicago,
      Illinois 60637

                
	 
      	
                  Facsimile
      Number: 773-702-0741

                
	 
      	 
      
	 
      	
                  Attention:
      Director of Technology
Transfer

                

        

      

      

      
        
          
            	
                    If
      to Licensee:

                  	
                    GenVec,
      Inc.

                  
	 
      	
                    65
      West Watkins Mill Road

                  
	 
      	
                    Gaithersburg,
      MD 20878

                  
	 
      	
                    Facsimile
      Number: 240-632-0735

                  
	 
      	 
      
	 
      	
                    Attention:
      President

                  

          

        

      

    

     

    *The
asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange
Commission

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          
            	 
      	
                    With
      a copy to: Vice President, Corporate
Development

                  

          

        

      

    

    

    
      	
               
      

            	
              3.

            	
              Schedule
      A shall be amended to include:

            

    

     

    
      
        
          
            
              
                
                  
                    
                      
                        	
                                Title:

                              	
                                Transcriptional
      Targeting of an Adenoviral Delivered Tumor Necrosis Factor Alpha by
      Temozolamide in Experimental Glioblastoma

                              
	
                                Inventors:

                              	
                                Weichselbaum
      and Kufe

                              
	
                                Application
      Number:

                              	
                                60/604,251

                              
	
                                File
      Date:

                              	
                                8-25-04

                              
	
                                University
      Reference:

                              	
                                1250

                              
	
                                DFCI
      Reference:

                              	
                                1021

                              

                      

                    

                  

                

              

            

          

        

      

    

     

    
      	
               
      

            	
              4.

            	
              Schedule
      A shall be amended to
delete:  "*"

            

    

     

    
      	
               
      

            	
              5.

            	
              Schedule
      A, 24. shall be replaced with:  "
*"

            

    

     

    Except as
specifically amended by this Amendment to AGREEMENT, all other terms and
conditions of the AGREEMENT shall remain in full force and effect without
modification. If there is any inconsistency or conflict between any provision in
this Amendment to AGREEMENT and any provision in the AGREEMENT, the provision in
this Amendment to AGREEMENT shall control.

     

    This
Amendment to AGREEMENT may be signed in counterparts, each of which shall be
deemed an original, all of which taken together shall be deemed one
instrument.

     

    IN
WITNESS WHEREOF, the Parties have duly executed this Amendment to AGREEMENT as
of the date first written above.

     

    
      
        
          
            
              
                	
                        University

                      	 
      	
                        GenVec,
      inc.

                      
	 
      	 
      	 
      	 
      	 
      
	
                        By:

                      	 
      	 
      	
                        By:

                      	 
      
	 
      	 
      	 
      	 
      	 
      
	
                        Title:

                      	
                          Director, UCTech

                      	 
      	
                        Title:

                      	
                          SVP

                      
	 
      	 
      	 
      	 
      	 
      
	
                        Date:

                      	
                          4/26/05

                      	 
      	
                        Date:

                      	
                        4/20/05

                      

              

            

          

        

      

    

     

    
      
        
          
            
              
                
                  	
                          DFCI

                        	 
      	 
	 
      	 
      	 
	
                          By:

                        	 
      	 
	 
      	
                          Anthony
      A. delCampo, M.B.A.

                        	 
	
                          Title:

                        	
                          Vice
      President

                        	 
	 
      	
                          Research
      and Technology Ventures

                        	 
	 
      	
                          Dana
      Farber Cancer Institute

                        	 
	 
      	 
      	 
	
                          Date:

                        	
                          5/5/05

                        	 

                

              

            

          

        

      

    

     

    *The asterisk denotes that
confidential portions of this exhibit have been omitted in reliance on Rule
24b-2 of the Securities Exchange Act of 1934. The confidential portions have
been submitted separately to the Securities and Exchange Commission

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]